0
No votes yet
Article

Managing Toxicities Associated With Antiangiogenic Biologic Agents in Combination With Chemotherapy for Metastatic Colorectal Cancer

Nina N. Grenon
CJON 2013, 17(4), 425-433 DOI: 10.1188/13.CJON.425-433

Toxicities commonly associated with antiangiogenic agents include hypertension, proteinuria, wound-healing complications, bleeding or hemorrhage, thromboembolic events, hypersensitivity reactions, and gastrointestinal perforation; however, toxicities most often attributed to chemotherapy include nausea, vomiting, diarrhea, constipation, fatigue, neuropathy, mucositis, hand-foot syndrome, hypersensitivity reactions, and myelosuppression. Patients with metastatic colorectal cancer (mCRC) who receive an antiangiogenic agent in combination with chemotherapy may experience toxicities related to both chemotherapy and the antiangiogenic agent. If possible, evidence-based interventions should be used for the management of toxicities. Patient education about expected toxicities and optimal toxicity management can promote the optimal use of therapy to improve survival and quality of life. Oncology nurses are well positioned to educate patients and their families on anticipated treatment and management of side effects. This article summarizes the incidence of toxicities associated with the antiangiogenic biologic agents aflibercept and bevacizumab, in combination with chemotherapy for patients with mCRC, and provides strategies for managing these toxicities based on clinical practice guidelines.

References 

Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield M. R., … Lyman, G. H. (2011). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>Journal of Clinical Oncology, 29</i>, 4189-4198.

Beatty, K., Winkelman, C., Bokar, J. A., & Mazanec, P. (2011). Advances in oncology care: Targeted therapies. <i>AACN Advanced Critical Care, 22</i>, 323-334.

Blowers, E., & Hall, K. (2009). Managing adverse events in the use of bevacizumab and chemotherapy. <i>British Journal of Nursing, 18</i>, 351-356, 358.

Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong R., … Saltz, L. (2011). XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer, 105</i>, 58-64.

Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., … Roccella, E. J. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <i>Hypertension, 42</i>, 1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2

Damron, B. H., Brant, J. M., Belansky, H. B., Friend, P. J., Samsonow, S., & Schaal, A. (2009). Putting evidence into practice: Prevention and management of bleeding in patients with cancer. <i>Clinical Journal of Oncology Nursing, 13</i>, 573-583. doi:10.1188/09.CJON.573-583

Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery M., … Barrueco, J. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. <i>Journal of Clinical Oncology, 25</i>, 4779-4786.

Gaya, A., & Tse, V. (2012). A preclinical and clinical review of aflibercept for the management of cancer. <i>Cancer Treatment Reviews, 38</i>, 484-493. doi:10.1016/j.ctrv.2011.12.008

Genentech. (2012). <i>Avastin® (bevacizumab)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://www.gene.com/download/pdf/avastin_prescribing.pdf'>http://www.gen...

Gerber, H. P., & Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. <i>Cancer Research, 65</i>, 671-680.

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., … & Benson, A. B. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. <i>Journal of Clinical Oncology, 25</i>, 1539-1544.

Giantonio, B. J., Chen, H. X., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., & Benson, A. I. B. (2004). Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. <i>Journal of Clinical Oncology, 22</i>(14, Suppl.), 3017.

Giantonio, B. J., Levy, D. E., O'Dwyer, P. J., Meropol, N. J., Catalano, P. J., & Benson, A. B. (2006). A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group study E2200. <i>Annals of Oncology, 17</i>, 1399-1403. doi:10.1093/annonc/mdl161

Gobel, B. H. (2007). Nursing considerations of bevacizumab use in multiple tumor types. <i>Oncology Nursing Forum, 34</i>, 693-701.

Grenon, N. N., & Chan, J. (2009). Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: A new guide for nurses. <i>Clinical Journal of Oncology Nursing, 13</i>, 285-296. doi:10.1188/09.CJON.285-296

Guan, Z. Z., Xu, J. M., Luo, R. C., Feng, F. Y., Wang, L. W., Shen, L., … Xu, R. H. (2011). Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial. <i>Chinese Journal of Cancer, 30</i>, 682-689.

Harris, D. J., Eilers, J., Harriman, A., Cashavelly, B. J., & Maxwell, C. (2008). Putting evidence into practice: Evidence-based interventions for the management of oral mucositis. <i>Clinical Journal of Oncology Nursing, 12</i>, 141-152. doi:10.1188/08.CJON.141-152

Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., … Rudge, J. S. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. <i>Proceedings of the National Academy of Sciences of the United States of America, 99</i>, 11393-11398.

Horita, Y., Yamada, Y., Kato, K., Hirashima, Y., Akiyoshi, K., Nagashima, K., … Shimada, Y. (2011). Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. <i>International Journal of Clinical Oncology, 17</i>, 604-609. doi:10.1007/s10147-011-0331-2

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim W., … Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. <i>The New England Journal of Medicine, 350</i>, 2335-2342.

Jin, K., Shen, Y., He, K., Xu, Z., Li, G., & Teng, L. (2010). Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer? <i>Clinical and Translational Oncology, 12</i>, 526-532.

Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., … Bergsland, E. (2003). Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology, 21</i>, 60-65.

Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., … Novotny, W. F. (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. <i>Journal of Clinical Oncology, 23</i>, 3697-3705. doi:10.1200/JCO.2005.05.112

Kopetz, S., Hoff, P. M., Morris J. S., Wolff R. A., Eng C., Glover K. Y., … Heymach J. V. (2010). Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. <i>Journal of Clinical Oncology, 28</i>, 453-459. doi:10.1200/JCO.2009.24.8252

Langewitz, W., Heydrich, L., Nübling, M., Szirt, L., Weber, H., & Grossman, P. (2010). Swiss Cancer League communication skills training programme for oncology nurses: An evaluation. <i>Journal of Advanced Nursing, 66</i>, 2266-2277.

Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., … Francis, C. W. (2007). American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. <i>Journal of Clinical Oncology, 25</i>, 5490-5505.

Mitchell, S. A., Beck, S. L., Hood, L. E., Moore, K., & Tanner, E. R. (2007). Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. <i>Clinical Journal of Oncology Nursing, 11</i>, 99-113. doi:10.1188/07.CJON.99-113

Moore, K., Johnson, G., Fortner, B. V., & Houts, A. C. (2008). The AIM Higher Initiative: New procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. <i>Clinical Journal of Oncology Nursing, 12</i>, 229-238. doi:10.1188/08.CJON.229-238

Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting evidence into practice: Evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. <i>Clinical Journal of Oncology Nursing, 13</i>, 336-341. doi:10.1188/09.CJON.336-341

National Cancer Institute. (2012). Oral complications of chemotherapy and head/neck radiation (PDQ®): Health professional version. Retrieved from <a target="_blank" href='http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/...

National Cancer Institute Cancer Dictionary. (n.d.a). Asthenia. Retrieved from <a target="_blank" href='http://www.cancer.gov/dictionary?cdrid=44787'>http://www.cancer.gov/dict...

National Cancer Institute Cancer Dictionary. (n.d.b). Fatigue. Retrieved from <a target="_blank" href='http://www.cancer.gov/dictionary?CdrID=321374'>http://www.cancer.gov/dic...

National Comprehensive Cancer Network. (2011). <i>NCCN Clinical Practice Guidelines in Oncology: Venous thromboembolic disease.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf'>http://www....

National Comprehensive Cancer Network. (2012a). <i>NCCN Clinical Practice Guidelines in Oncology: Antiemesis.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf'>http...

National Comprehensive Cancer Network. (2012b). <i>NCCN Clinical Practice Guidelines in Oncology: Cancer- and chemotherapy-induced anemia.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf'>http://w...

National Comprehensive Cancer Network. (2012c). <i>NCCN Clinical Practice Guidelines in Oncology: Cancer-related fatigue.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf'>http://...

National Comprehensive Cancer Network. (2012d). <i>NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf'>...

National Comprehensive Cancer Network. (2012e). <i>NCCN Clinical Practice Guidelines in Oncology: Palliative care.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf'>http...

National Comprehensive Cancer Network. (2013). <i>NCCN Clinical Practice Guidelines in Oncology: Colon cancer.</i> Retrieved from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'>http://ww...

Oncology Nursing Society. (2013a). Putting Evidence Into Practice. Diarrhea. Retrieved from <a target="_blank" href='http://www.ons.org/Research/PEP/Diarrhea'>http://www.ons.org/Research/PE...

Oncology Nursing Society. (2013b). Putting Evidence Into Practice. <i>Skin Reactions: Rash, Palmar-Plantar Erythrodysesthesia, Xerosis, Paronychia, Photosensitivity, and Pruritus. Expert Opinion Table.</i> Retrieved from <a target="_blank" href='http://www.ons.org/Research/PEP/media/ons/docs/research/outcomes/skin/ex...

Ouwerkerk, J., & Boers-Doets, C. (2010). Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. <i>European Journal of Oncology Nursing, 14</i>, 337-349. doi:10.1016/j.ejon.2010.03.004

Peterson, D. E., Bensadoun, R. J., & Roila, F. (2011). Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. <i>Annals of Oncology, 22</i>(Suppl. 6), vi78-vi84. doi:10.1093/annonc/mdr391

Regeneron Pharmaceuticals/Sanofi-Aventis U. S. (2012). <i>Zaltrap® (ziv-aflibercept)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://products.sanofi.us/zaltrap/zaltrap.html'>http://products.sanofi.u...

Saif, M. W. (2009). Managing bevacizumab-related toxicities in patients with colorectal cancer. <i>The Journal of Supportive Oncology, 7</i>, 245-251.

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., … Cassidy, J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. <i>Journal of Clinical Oncology, 26</i>, 2013-2019. doi:10.1200/JCO.2007.14.9930

Schiffer, C. A., Anderson, K. C., Bennett, C. L., Bernstein, S., Elting, L. S., Goldsmith, M., … Wagnon, A. H. (2001). Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Cancer Society of Clinical Oncology. <i>Journal of Clinical Oncology, 19</i>, 1519-1538.

Sher, A., & Wu, S. (2011). Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy—A meta-analysis. <i>Acta Oncologica, 50</i>, 997-1005.

Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. <i>CA: A Cancer Journal for Clinicians, 62</i>, 10-29.

Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., … Wolff, A. C. (2006). 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. <i>Journal of Clinical Oncology, 24</i>, 3187-3205. doi:10.1200/JCO.2006.06.4451

Sobrero, A., Ackland, S., Clarke, S., Perez-Carrión, R., Chiara S., Gapski, J., … Young, S. (2009). Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. <i>Oncology, 77</i>, 113-119. doi:10.1159/000229787

Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N., Makrantonakis, P., … Polyzos, A. (2012). Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). <i>British Journal of Cancer, 106</i>, 453-459. doi:10.1038/bjc.2011.594

Tang, P., Cohen, S. J., Bjarnason, G. A., Kollmannsberger, C., Virik, K., MacKenzie, M. J., … Moore, M. J. (2008). Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. <i>Journal of Clinical Oncology, 26</i>(15, Suppl.), 4027.

Tew, W. P., Gordon, M., Murren, J., Dupont, J., Pezzulli, S., Aghajanian, C., … Spriggs, D. R. (2010). Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. <i>Clinical Cancer Research, 16</i>, 358-366. doi:10.1158/1078-0432.CCR-09-2103

Tipton, J. M., McDaniel, R. W., Barbour, L., Johnston, M. P., Kayne, M., … Ripple, M. L. (2007). Putting evidence into practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. <i>Clinical Journal of Oncology Nursing, 11</i>, 69-78. doi:10.1188/07.CJON.69-78

Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., … Allegra, C. (2012). Addition of aflibercept to FOLFIRI improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>Journal of Clinical Oncology, 30</i>, 3499-3506. doi:10.1200/JCO.2012.42.8201

Verheul, H. M., & Pinedo H. M. (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. <i>Nature Reviews Cancer, 7</i>, 475-485.

Viale, P. H. (2010). Incorporating new data on colorectal cancer into nursing practice. <i>Clinical Journal of Oncology Nursing, 14</i>, 92-100. doi:10.1188/10.CJON.92-100

Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. <i>Clinical Journal of Oncology Nursing, 11</i>, 901-913. doi:10.1188/07.CJON.901-913

Wilkes, G. M. (2005). Therapeutic options in the management of colon cancer: 2005 update. <i>Clinical Journal of Oncology Nursing, 9</i>, 31-44. doi:10.1188/05.CJON.31-44

Woolery, M., Bisanz, A., Lyons, H. F., Gaido, L., Yenulevich, M., Fulton, S., & McMillan, S. C. (2008). Putting evidence into practice: Evidence-based interventions for the prevention and management of constipation in patients with cancer. <i>Clinical Journal of Oncology Nursing, 12</i>, 317-337. doi:10.1188/08.CJON.317-337